<?xml version="1.0" encoding="UTF-8"?>
<p id="para0015">With an effective reduction of pulmonary viral load in a murine model of SARS-CoV infection, potent antiviral activity against SARS-CoV-2, acceptable safety profile of parenteral remdesivir therapy in two case reports, and a randomised trial of Ebola virus disease, the clinical use of remdesivir in the cases of COVID-19 is are highly anticipated. Two randomised clinical trials of parenteral remdesivir therapy in the treatment of COVID-19 in China may open the window for effective antiviral therapy for such an epidemic infectious disease.</p>
